One candidate drug aiming to suppress ngf was a monoclonal antibody called tanezumab, owned by Pfizer, an American pharmaceutical firm.

一种旨在抑制 ngf 的候选药物是一种名为 tanezumab 的单克隆抗体，由美国制药公司辉瑞公司拥有。

Nevertheless, the fda rejected tanezumab in March 2021, owing to risks that its use might desensitise the patients to joint damage and thereby accelerate the spread of their disease.

尽管如此，FDA 还是在 2021 年 3 月拒绝了 tanezumab，因为它的使用可能会使患者对关节损伤不敏感， 从而加速疾病的传播。